Replies to post #24824 on Relief Therapeutics Holding AG (RLFTF)

[changes_iv]

There are two known receptors for the vasoactive intestinal peptide (VIP) termed VPAC1 and VPAC2. These receptors bind both VIP and pituitary adenylate cyclase-activating polypeptide (PACAP) to some degree. Both receptors are members of the 7 transmembrane G protein-coupled receptor family. https://en.wikipedia.org/wiki/Vasoactive_intestinal_peptide_receptor
Then... “Summary:
RLF-100 blocks the COVID-19 Virus, prevents a cytokine storm, heals the lungs and improves blood oxygenation with a mortality reduction of oyver 90% in the most severe cases.”

https://www.reddit.com/r/investing/comments/ihjz24/rlftf_the_most_promising_covid19_stock_drug/